Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Amyloidosis.

M A Gertz1, M Q Lacy, A Dispenzieri

  • 1Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Hematology/Oncology Clinics of North America
|January 8, 2000
PubMed
Summary
This summary is machine-generated.

Amyloidosis, though rare, presents with symptoms like kidney problems and heart failure. Early diagnosis via biopsy and Congo red staining, followed by chemotherapy, is crucial for managing this condition.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design.

Leukemia·2024
Same author

Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience.

Blood cancer journal·2023
Same author

"Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience.

Blood cancer journal·2021
Same author

Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients.

Blood cancer journal·2021
Same author

Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design.

Leukemia·2021
Same author

Systemic amyloidosis from A (AA) to T (ATTR): a review.

Journal of internal medicine·2020
Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026
Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026
See all related articles

Area of Science:

  • Internal Medicine
  • Oncology
  • Nephrology

Background:

  • Amyloidosis incidence is comparable to Hodgkin's disease and chronic granulocytic leukemia.
  • Consider amyloidosis in patients with unexplained nephrotic-range proteinuria, heart failure, peripheral neuropathy, or hepatomegaly.

Observation:

  • Monoclonal protein detection in patients with the above clinical presentations warrants further investigation.
  • Subcutaneous fat tissue provides a simple source for diagnostic biopsy material.

Findings:

  • Biopsy specimens stained with Congo red are essential for diagnosing amyloidosis.
  • Chemotherapy, including oral low-dose or high-dose with stem cell rescue, is a primary treatment modality.

Implications:

  • Increased awareness of amyloidosis symptoms can lead to earlier diagnosis.
  • Timely diagnosis and appropriate chemotherapy improve patient outcomes for amyloidosis.